Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2005 2
2006 1
2009 1
2011 2
2014 3
2015 5
2016 3
2017 6
2018 5
2019 8
2020 6
2021 4
2022 6
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Bishnoi S, Kotasek D, Aghmesheh M, Yau T, Cosman R, Prawira A, Moore M, Chan SL, Mant A, Eek R, Zielinski R, Su R, Pan Z, Ma Y, Li F, Li P, Tse AN. Bishnoi S, et al. Among authors: aghmesheh m. Cancer. 2024 Feb 26. doi: 10.1002/cncr.35226. Online ahead of print. Cancer. 2024. PMID: 38404184
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma.
Turner RJ, Guy TV, Geraghty NJ, Splitt A, Watson D, Brungs D, Carolan MG, Miller AA, de Leon JF, Aghmesheh M, Sluyter R. Turner RJ, et al. Among authors: aghmesheh m. Int J Mol Sci. 2023 Aug 8;24(16):12538. doi: 10.3390/ijms241612538. Int J Mol Sci. 2023. PMID: 37628721 Free PMC article.
Progress in the Treatment of Small Intestine Cancer.
Symons R, Daly D, Gandy R, Goldstein D, Aghmesheh M. Symons R, et al. Among authors: aghmesheh m. Curr Treat Options Oncol. 2023 Apr;24(4):241-261. doi: 10.1007/s11864-023-01058-3. Epub 2023 Feb 24. Curr Treat Options Oncol. 2023. PMID: 36826686 Review.
Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers.
Siu DHW, Ali A, Tjokrowidjaja A, De Silva M, Lee J, Clingan PR, Aghmesheh M, Brungs D, Mapagu C, Goldstein D, O'Neill S, Liauw WS, Sjoquist KM, Thomas D, Pavlakis N, Clarke SJ, Diakos C, Chantrill LA. Siu DHW, et al. Among authors: aghmesheh m. Asia Pac J Clin Oncol. 2022 Dec;18(6):660-668. doi: 10.1111/ajco.13745. Epub 2022 Jan 30. Asia Pac J Clin Oncol. 2022. PMID: 35098672
Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy.
Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, Nagrial AM, Bartholomeusz D, Hendlisz A, Ajithkumar T, Iwuji C, Wilson NE, Turner DM, James DC, Young E, Harris MT. Ross PJ, et al. Among authors: aghmesheh m. ESMO Open. 2022 Feb;7(1):100356. doi: 10.1016/j.esmoop.2021.100356. Epub 2021 Dec 23. ESMO Open. 2022. PMID: 34953400 Free PMC article.
53 results